Cytokine-Targeted Antipsoriatic Drug Development Services

Cytokines are key regulators in the immune response and play a pivotal role in the pathogenesis of psoriasis. At Ace Therapeutics, we specialize in preclinical research and development with a distinct focus on cytokine-targeted antipsoriatic drugs. By focusing on the intricate cytokine networks that drive psoriatic pathology, we empower our clients to develop targeted and effective therapies.

Overview of Cytokine-Targeted Antipsoriatic Drugs

Cytokines such as interleukin-12 (IL-12), interleukin-17 (IL-17), and interleukin-23 (IL-23) play pivotal roles in the pathogenesis of psoriasis. IL-23, for instance, is crucial in the differentiation of naïve T cells into pathogenic Th17 cells. These cells produce inflammatory cytokines that drive keratinocyte proliferation and sustain the inflammatory cycle. The levated levels of IL-17 and IL-23 correlate with the severity of psoriasis, making them prime targets for therapeutic intervention. Various biologic therapies have emerged, focusing on different cytokine pathways:

• TNF-α Inhibitors: Early biologics like etanercept and infliximab target tumor necrosis factor-alpha (TNF-α), a cytokine involved in systemic inflammation. While effective, their use is often limited by adverse effects and the need for frequent administration.
• IL-12/23 Inhibitors: Ustekinumab, the first biologic targeting the shared p40 subunit of IL-12 and IL-23, has shown efficacy in reducing psoriasis severity. However, blocking IL-12 may also hinder its protective effects.
• IL-17 Inhibitors: Agents such as secukinumab and ixekizumab specifically target IL-17A, resulting in significant improvements in skin clearance and overall patient quality of life.
• IL-23 Inhibitors: Newer therapies like guselkumab and risankizumab selectively inhibit p19 subunit of IL-23, providing enhanced efficacy with potentially fewer side effects, as they do not affect IL-12 signaling.

Fig. 1 Roles of cytokines in psoriasis. (Strychalski ML, et al., 2022)

Comprehensive Cytokine-Targeted Antipsoriatic Drug Development Services

Ace Therapeutics provides a comprehensive suite of services tailored to the development of cytokine-targeted antipsoriatic drugs. We support our clients through each stage of drug development, from target identification to preclinical evaluation.

Target Identification and Validation

Leveraging our deep understanding of psoriatic pathology, we provide comprehensive services such as identifying and validating novel cytokine targets. Our approach integrates genomics, proteomics, and bioinformatics to ensure that the targets are not only relevant but also amenable to therapeutic intervention.

Drug Design and Optimization

Our drug design services focus on developing molecules that are highly selective and potent against their intended targets. We employ a range of techniques, including rational design and structure-based drug design, to optimize the pharmacological properties of your candidates.

Preclinical Studies

Our preclinical services encompass a broad spectrum of studies, from in vitro assays to in vivo models. We are equipped to evaluate the efficacy, safety, and pharmacokinetics of antipsoriatic drugs, providing a solid foundation for drug development.

The evolving landscape of psoriasis treatment, driven by advancements in cytokine biology, presents significant opportunities for innovative therapies. Ace Therapeutics is dedicated to supporting clients in the research and development of cytokine-targeted antipsoriatic drugs. Contact us today to learn more about our comprehensive services and how we can support your drug development projects.